Journal of Antimicrobial Chemotherapy (2000) 46, 741-749
© 2000 The British Society for Antimicrobial Chemotherapy
Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora
a Huddinge University Hospital, Karolinska Institute, b Södertörns högskola, University College, Stockholm, Sweden; c Aventis Pharma, Hoechst Marion Roussel, Romainville, France
The pharmacokinetics in plasma and saliva of a new ketolide, telithromycin (HMR 3647), and the effect on the normal oropharyngeal and intestinal microflora were studied in healthy volunteers and compared with those of clarithromycin. Ten subjects received 800 mg telithromycin perorally once daily and 10 other subjects received 500 mg clarithromycin bid for 10 days. Blood, saliva and faecal specimens were collected at defined intervals before, during and after administration for pharmacokinetic and microbiological analyses. In subjects receiving telithromycin, the mean Cmax, AUC and C24 (24 h) in saliva exceeded the values obtained from plasma, while saliva and serum pharmacokinetic parameters were in the same range for the clarithromycin group. The quantitative ecological disturbances in the normal microflora during administration of telithromycin were moderate and comparable to those associated with clarithromycin administration. No overgrowth of yeasts or Clostridium difficile occurred. Emergence of resistant strains was seen in both treatment groups. Administration of both telithromycin and clarithromycin was associated with significant increases in MICs for intestinal Bacteroides isolates, which persisted 2 weeks after discontinuation of treatment. In addition, a significant emergence of highly clarithromycin-resistant 
-haemolytic streptococci, intestinal enterococci and Enterobacteriaceae was detected at day 10 in the clarithromycin group. In conclusion, administration of telithromycin resulted in high drug levels in saliva, which indicates a good therapeutic profile for throat infections. Telithromycin seems to have a more favourable ecological profile compared with clarithromycin in terms of resistance development in the normal microflora.
* Correspondence address. Department of Microbiology, Pathology and Immunology, F82, Huddinge University Hospital, SE-141 86 Stockholm, Sweden. Tel: +46-8-585-878-38; Fax: +46-8-711-3918; E-mail: charlotta.edlund{at}impi.ki.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Kasbekar and P. S. Acharya Telithromycin: The first ketolide for the treatment of respiratory infections Am. J. Health Syst. Pharm., May 1, 2005; 62(9): 905 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tanaka, Y. Fukuda, S. Shintani, K. Hori, T. Tomita, T. Ohkusa, T. Matsumoto, and H. Miwa Influence of antimicrobial treatment for Helicobacter pylori infection on the intestinal microflora in Japanese macaques J. Med. Microbiol., March 1, 2005; 54(3): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. F. Berg, J. H. T. Tjhie, G.-J. Scheffer, M. F. Peeters, P. H. J. van Keulen, J. A. J. W. Kluytmans, and E. E. Stobberingh Emergence and Persistence of Macrolide Resistance in Oropharyngeal Flora and Elimination of Nasal Carriage of Staphylococcus aureus after Therapy with Slow-Release Clarithromycin: a Randomized, Double-Blind, Placebo-Controlled Study Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4183 - 4188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Farrell, S G Jenkins, and R R Reinert Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators J. Med. Microbiol., November 1, 2004; 53(11): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Low, M. E. Pichichero, and U. B. Schaad Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Malhotra-Kumar, C. Lammens, A. Martel, C. Mallentjer, S. Chapelle, J. Verhoeven, M. Wijdooghe, F. Haesebrouck, and H. Goossens Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium J. Antimicrob. Chemother., February 1, 2004; 53(2): 271 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Clark and E. Langston Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Mayo Clin. Proc., September 1, 2003; 78(9): 1113 - 1124. [Abstract] [PDF]
|
|
|
|
|
|
A.-C. Cremieux, C. Muller-Serieys, X. Panhard, F. Delatour, M. Tchimichkian, F. Mentre, and A. Andremont Emergence of Resistance in Normal Human Aerobic Commensal Flora during Telithromycin and Amoxicillin-Clavulanic Acid Treatments Antimicrob. Agents Chemother., June 1, 2003; 47(6): 2030 - 2035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ackermann and A. C. Rodloff Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide J. Antimicrob. Chemother., March 1, 2003; 51(3): 497 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Noreddin, D. Roberts, K. Nichol, A. Wierzbowski, D. J. Hoban, and G. G. Zhanel Pharmacodynamic Modeling of Clarithromycin against Macrolide-Resistant [PCR-Positive mef(A) or erm(B)] Streptococcus pneumoniae Simulating Clinically Achievable Serum and Epithelial Lining Fluid Free-Drug Concentrations Antimicrob. Agents Chemother., December 1, 2002; 46(12): 4029 - 4034. [Abstract] [Full Text] [PDF]
|
|